**Press Release For immediate release**

**Trelleborg Releases Whitepaper on Silicone Drug-Eluting Combination Devices**

St. Louis Park, MN, June, 2022 – Trelleborg’s Healthcare & Medical business releases a technical whitepaper discussing the different manufacturing processes of combining silicone with Advanced Pharmaceutical Ingredients (APIs), the pros and cons, and test results that prove the effectiveness of the elution method in drug-eluting devices.

Zach Fletcher, Business Development Manager for Drug Combination Devices, and author of the whitepaper, says: “Single entity combination devices continue to show promise for providing novel solutions to some of the most challenging conditions patients face today.

“Silicone stands out as one of the most successful materials to support the production and advancement of combination products. Its biocompatibility and porousness make it a perfect fit for the growing market of implantable devices. When medical device manufacturers are supported by component suppliers early in the product development cycle, they can navigate all manufacturing considerations and determine the best method for adding API to silicone.”

The whitepaper on silicone drug-eluting combination devices is just one of the free resources available to medical device manufacturers via Trelleborg’s Healthcare & Medical website. Website visitors can find webinars and engineering tools designed to support engineers by simplifying material and product selection. Go to <https://www.trelleborg.com/en/healthcare/tools-and-media>

To download a copy of the Advanced Pharmaceutical Ingredients whitepaper, go to: <https://www.trelleborg.com/en/healthcare/tools-and-media/technical-library/api-whitepaper>

**-ENDS-**

**For more information, please contact:**Sophie Hudson  
Tel: +44 (0) 7817 093930  
Email: sophie.hudson@trelleborg.com

**About Trelleborg Healthcare & Medical and Trelleborg Group**

***Trelleborg Healthcare & Medical*** *helps pharmaceutical and medical device​ companies improve patient quality of life. ​It does this by forming lasting partnerships with customers to develop innovative, reliable engineered polymer solutions for demanding medical, biotech and pharmaceutical applications. From a single global source, backed by the expertise of a worldwide engineering and manufacturing network, it partners with its customers in all stages of development, from concept to serial production, providing the optimum solutions to meet all their partners polymer-based healthcare & medical application challenges. Trelleborg Healthcare & Medical combines a number of operations from within Trelleborg Group that are focused on this industry.* [*www.trelleborg.com/healthcare*](https://ddec1-0-en-ctp.trendmicro.com/wis/clicktime/v1/query?url=https%3a%2f%2fnortheuroper%2dnotifyp.svc.ms%3a443%2fapi%2fv2%2ftracking%2fmethod%2fClick%3fmi%3d4XV89ZMPkUimdgREcNjO6w%26tc%3dLink%26cs%3d7c970e432f295cd87fc48ad31e7cf76d%26ru%3dhttp%253a%252f%252fwww.trelleborg.com%252fhealthcare&umid=0d61ad59-86de-41a5-ae23-c922968990a6&auth=b6670b9751c5c90ededae23711566d84a7ddb070-673d43a3086e3559956d35e285fbd29d316bd08d)

***Trelleborg*** *is a world leader in engineered polymer solutions that seal, damp and protect critical applications in demanding environments. Its innovative solutions accelerate performance for customers in a sustainable way. The Trelleborg Group has annual sales of about SEK 34 billion (EUR 3.34 billion, USD 3.95 billion) and operations in about 50 countries. The Group comprises three business areas: Trelleborg Industrial Solutions, Trelleborg Sealing Solutions and Trelleborg Wheel Systems. The Trelleborg share has been listed on the Stock Exchange since 1964 and is listed on Nasdaq Stockholm, Large Cap.* [*www.trelleborg.com*](http://www.trelleborg.com)*.*